Ruxolitinib for Acute GVHD

FDA Approves Ruxolitinib For Acute Graft Versus Host Disease

Reuters (5/24, Babu, Maddipatla) reported the Food and Drug Administration approved Incyte Corp.'s Jakafi (ruxolitinib) "for acute Graft versus Host disease (GvHD)." The drug was previously "approved for treating certain bone marrow and blood disorders in the" US, and is now "the only FDA-approved treatment for GvHD."

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.